Drug profile · INN
tobramycin
PFIZER AUSTRALIA PTY LTD
tobramycin (PFIZER AUSTRALIA PTY LTD) is a 70s ribosome inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — tobramycin
- US status
- approved
- Class
- Antiinfectives for systemic use (J01)
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 8
- Data quality
- 0.89
Quick answer
tobramycin (PFIZER AUSTRALIA PTY LTD) is a 70s ribosome inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
70S ribosome inhibitor
Primary target: 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tobramycin?
tobramycin (PFIZER AUSTRALIA PTY LTD) is a 70s ribosome inhibitor. Associated with Pfizer Australia Pty Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for tobramycin?
PFIZER AUSTRALIA PTY LTD is a marketed brand name for tobramycin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tobramycin?
tobramycin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.